Aurora Cannabis Inc.

TSX:ACB.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$6.31 +0.48%

+$0.02 today

Market cap
$414.85M
Beta
1.34
P/E (TTM)
-3.2
EPS (TTM)
-$1.31
52W Low $3.77High $9.33

Volume 0.32M

Average 0.42M

ACB.TO Debt Repayment

Cash used to repay borrowings during the period.

Aurora Cannabis Inc.TSX: ACB.TO

Debt Repayment · Q4 FY2026 · quarter ended Mar 2026

Debt repayment dips below year-ago levels

Q4 FY2026 debt repayment of CA$37K fell 98.4% year over year, behind the +100.0% change in trailing-twelve-month debt repayment. Sequentially, it fell 98.1% from the prior quarter.

Context

  • Debt repayment amounted to 1.6% of revenue in FY2026, up 1.3 pp from a year earlier.
  • Debt repayment grew in size in 1 of the last 2 fiscal years.

What to watch

Whether quarterly growth recovers from -98.4% toward the trailing-twelve-month pace of +100.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$37K-98.1% QoQ
Last fiscal yearMar 2026
-CA$5.02M+523.5% YoY
LTMMar 2026
CA$0+100.0% YoY
Debt Repayment past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-98.4%——
1 year+523.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Debt Repayment history

CAD · from the cash flow

Latest · FY2026
(5.02M) CAD
Year-over-year change
-523.5%

Debt Repayment vs competitors

How ACB.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so debt repayment is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +100.0% is the 2nd highest of 7, against a peer median of -22.2%.
  • Debt repayment amounts to 0.0% of revenue for ACB.TO, versus a peer median of 13.3%.
ACB.TO Competitors
Debt Repayment for ACB.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
WEED.TOCanopy Growth CorporationLTM Mar 2026CA$41.44M CAD-81.2%—13.3%
CPH.TOCipher Pharmaceuticals Inc.LTM Mar 2026$40.19M USD-201.1%+759.9%78.9%
FRX.TOFennec Pharmaceuticals Inc.LTM Mar 2026$19.82M USD——38.7%
EDT.TOSpectral Medical Inc.LTM Mar 2026CA$19.22M CAD+97.4%+37.6%696.2%
XLY.TOAuxly Cannabis Group Inc.LTM Mar 2026CA$7.88M CAD-56.5%+7.4%5.0%
TSND.TOTerrAscend Corp.LTM Mar 2026$3.77M USD+142.4%+435.7%1.4%
OGI.TOOrganiGram Holdings Inc.LTM Mar 2026CA$1.05M CAD+12.1%—0.4%
ACB.TOAurora Cannabis Inc.LTM Mar 2026CA$0 CAD+100.0%—0.0%
Peer median (excluding ACB.TO) —-22.2%+236.7%13.3%

Competitors are the stored peer set for ACB.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CAD
Metric
FY2022
Jun 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
FY2026
Mar 2026
Net Income(1.72B)(265.33M)(59.05M)15.76M(58.62M)
Depreciation & Amortization93.66M43.57M33.07M22.55M14.19M
Deferred Income Tax(2.19M)(18.4M)(1.67M)(3.19M)55K
Stock-Based Compensation13.76M16.89M12.72M11.52M7.29M
Change in Working Capital52.65M(25.12M)(15.63M)10.21M(9.21M)
Accounts Receivables18.34M5.53M(4.33M)5.24M(8.15M)
Inventory21.07M49.03M3.62M(15.05M)7.44M
Accounts Payables6.77M(8.06M)(15.7M)14.91M(8.04M)
Other Working Capital6.48M(71.61M)790K5.11M(9.21M)
Other Non-Cash Items1.45B190.11M(37.96M)(40.85M)54.32M
Operating Cash Flow(110.27M)(115.82M)(68.51M)16.01M(13.51M)
Capital Expenditures(32.21M)(12.13M)(16.96M)(18.86M)(22.55M)
Acquisitions (Net)(23.42M)(18.54M)(5.55M)01.1M
Purchases of Investments00000
Sales of Investments03.36M4.99M5.49M0
Other Investing Activities19.46M16K12.02M(956K)(51.98M)
Investing Cash Flow(36.17M)(27.29M)(5.49M)(14.33M)(73.43M)
Debt Repayment(170.83M)—(85.76M)(805K)(5.02M)
Common Stock Issued350.19M73.19M37.93M00
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(31.58M)(95.21M)(89K)689K(154K)
Financing Cash Flow147.78M(56.48M)(47.92M)(116K)9.76M
Effect of Forex Changes15.01M15.54M297K264K4.33M
Net Change in Cash16.35M(140.01M)(121.5M)1.83M(72.85M)
Free Cash Flow(142.48M)(127.95M)(85.46M)(2.85M)(36.06M)

Aurora Cannabis Inc.

TSX:ACB.TO

Intrinsic Alpha fair value

Locked

Current Price

$6.31

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.